Our initial focus on clinical research is to provide patients suffering from severe forms of epilepsy access to our proprietary phyto-cannabinoid treatment EP1.
EP1 is approved in Israel for the treatment of drug resistant epilepsy. EP1 was part of a two-year clinical trial of 130 patients conducted by the Israeli Ministry of Health that resulted in significant reductions in seizures as well as seizure free patients.
Phase 2 Clinical Trial with paediatric and adult patients with drug resistant epilepsy at 2 major Australian hospital sites. Ethics approved with recruitment to start in 2020.
We also have a deep pipeline of additional cannabinoid product candidates which includes adult epilepsy, autism, a number of cancers, pain and neurological conditions caused by damage to the central nervous system and terminal illnesses. Our drug discovery and development process pipeline extends to other cancers where patients are refractory to current therapeutic treatment.
Collaborations have enabled us to assemble a large team to drive rigorous clinical research in medical cannabis (MC) treatments. This will translate to registered therapeutic products in AU, US and EU markets, increase employment opportunities, and grow the Israeli MC economy.
Academics at Technion, Israel; University of Melbourne, Australia; and University of Auckland, New Zealand
Pediatric neurologists at Austin Health, Alfred Health and Auckland University Liggins Institute for Neuroscience Research
Supply chain managers (Anspec), manufacturers in Israel (Panaxia), clinical trial and medical monitors (Neuroscience Trials Australia), improved drug delivery for MC treatment (SUDA)
If you are interested in working with Cann Pharma regarding specific investigator initiated pre-clinical and clinical research, please contact Cann Pharma via email.